New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The Ma’anshan site approval covers pastilles, oral liquids, and powders
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Subscribe To Our Newsletter & Stay Updated
